About this trial
The main purpose of this study is to profile exosomes isolated from the plasma of women diagnosed with Triple Negative Breast Cancer (TNBC) during routine treatment and follow up in the oncology clinic using Nanoparticle tracking analysis (NTA) and Raman/infra-red spectroscopy. Another objective is to investigate if the individual exosome patient signature can be used as:
A) a predictive marker of response to treatment, and/or
B) a prognostic biomarker
Patient Profile
Eligible patients have either early TNBC and are receiving neoadjuvant chemotherapy or starting a new line of systemic treatment for metastatic TNBC.
Where’s this trial being run?
St Vincents University Hospital and Mater Misericordiae University Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | Exosomes in TNBC |
|---|---|
| Number: | 22-21 |
| Full Title: | Pilot longitudinal study, using nanoparticle tracking analysis, raman spectroscopy, mass spectroscopy and glycosylation analyses to profile exosomes isolated from the sera of women diagnosed with triple negative breast cancer (TNBC). |
| Principal Investigator: | Professor Michaela Higgins |
|---|---|
| Type: | Collaborative |
| Sponsor: | University College Dublin |
| Recruitment Started: |
Global: n/a Ireland: 2017 |
| Global Recruitment Target: | n/a |
|---|---|
| Ireland Recruitment Target: | 40 |